Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients-Reference-Cited by-同舟云学术

Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients

Published:2010-10-19 Issue:5 Volume:151 Page:509-515
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Rigano Paolo,Pecoraro Alice,Calzolari Roberta,Troia Antonio,Acuto Santina,Renda Disma,Pantalone Gaetano Restivo,Maggio Aurelio,Marzo Rosalba Di

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2010.08397.x/fullpdf

Reference32 articles.

1. Successful use of hydroxyurea in beta-thalassemia major;Arruda;New England Journal of Medicine,1997

2. Pharmacological induction of fetal hemoglobin in sickle cell disease and β-thalassemia;Atweh;Seminars in Hematology,2001

3. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia;Bradai;Transfusion,2007

4. Induction of gamma-globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients;Calzolari;British Journal of Haematology,2008

5. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia;Charache;Blood,1992

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How I treat non-transfusion-dependent β-thalassemia;Blood;2023-09-14

2. Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy;Drug Design, Development and Therapy;2023-05

3. Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias;Cochrane Database of Systematic Reviews;2023-01-13

4. Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective;Pharmaceuticals;2022-06-16

5. The use of hydroxyurea in the real life of MIOT network: an observational study;Expert Opinion on Drug Safety;2022-04-17